Analyst Price Targets — RPRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 10, 2026 12:56 pm | Terence Flynn | Morgan Stanley | $63.00 | $47.98 | TheFly | Royalty Pharma price target raised to $63 from $61 at Morgan Stanley |
| February 27, 2026 6:43 pm | — | Seaport Global | $50.00 | $46.21 | StreetInsider | Royalty Pharma (RPRX) PT Raised to $50 at TD Cowen |
| February 12, 2026 1:14 pm | Terence Flynn | Morgan Stanley | $61.00 | $44.71 | TheFly | Royalty Pharma price target raised to $61 from $56 at Morgan Stanley |
| January 30, 2026 9:40 am | Ashwani Verma | UBS | $49.00 | $40.86 | TheFly | Royalty Pharma upgraded to Buy from Neutral at UBS |
| December 11, 2025 3:12 pm | — | Leerink Partners | $45.00 | $38.22 | StreetInsider | Royalty Pharma (RPRX) PT Raised at TD Cowen; 'Best Ideas 2026: Unique Business' |
| September 30, 2025 9:10 am | — | Goldman Sachs | $42.00 | $35.25 | TheFly | Royalty Pharma initiated with a Buy at Goldman Sachs |
| July 10, 2025 12:34 pm | Terence Flynn | Morgan Stanley | $54.00 | $36.14 | TheFly | Royalty Pharma price target raised to $54 from $51 at Morgan Stanley |
| September 4, 2024 7:44 am | Chris Shibutani | Goldman Sachs | $51.00 | $29.16 | StreetInsider | Goldman Sachs Reiterates Buy Rating on Royalty Pharma (RPRX) |
| July 11, 2024 8:15 am | Terence Flynn | Morgan Stanley | $51.00 | $25.73 | TheFly | Royalty Pharma price target raised to $51 from $48 at Morgan Stanley |
| June 7, 2024 4:57 am | Chris Shibutani | Goldman Sachs | $50.00 | $27.09 | StreetInsider | Royalty Pharma (RPRX) PT Raised to $50 at Goldman Sachs |
Latest News for RPRX
NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary share.
NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Aberdeen Group plc grew its stake in shares of Royalty Pharma PLC (NASDAQ: RPRX) by 17.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 661,416 shares of the biopharmaceutical company's stock after purchasing an additional 98,191 shares during the quarter. Aberdeen Group
Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) CFO Terrance Coyne sold 34,791 shares of the company's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $48.33, for a total transaction of $1,681,449.03. Following the transaction, the chief financial officer owned 32,916 shares of the company's stock,
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RPRX.
U.S. House Trading
No House trades found for RPRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.